1、1CITELINE.COMKEY POTENTIAL DRUG LAUNCHES IN 2025(AS OF JULY 2024)As a supplement to our well-known quarterly outlook report,Biomedtracker is pleased to present a longer-term look at some key late-stage drugs projected to hit the market in 2025.These drugs represent new drug classes,major changes to

2、standards of care,and/or large market opportunities across the wide range of indications covered by Biomedtracker and Datamonitor Healthcare.Key Potential Drug Launches in 2025The information in this presentation,including likelihood of approval(LOA)ratings and upcoming catalysts,is up to date as of

3、 July 2024.More details about each drug can be viewed instantly on Biomedtracker by clicking the icon.2CITELINE.COMKEY POTENTIAL DRUG LAUNCHES IN 2025(AS OF JULY 2024)This report covers the following indications:ContentsEndocrineAcromegalyCongenital Adrenal Hyperplasia(CAH)Congenital Hyperinsulinism

4、(CHI)Type 1 DiabetesDiabetic NephropathyHematologyFanconi AnemiaHemophilia AHemophilia A and BThalassemiaInfectious DiseasesFungal Infections-SystemicHIV PreventionMeningococcal VaccinesSeasonal Influenza VaccinesUrinary Tract and Reproductive Tract Infections(Antibacterial)AllergyAtopic Dermatitis(

5、Eczema)Autoimmune/Immunology(A&I)Crohns disease DermatomyositisGraft vs.Host Disease(GVHD)-TreatmentImmunoglobulin G4-related disease(IgG4-RD)Myasthenia GravisPsoriasisPsoriatic arthritis Ulcerative ColitisCardiovascular(CV)Cardiomyopathy-DilatedChronic Heart Failure Preserved Ejection Fraction(Chro

6、nic HFpEF)Dyslipidemia/HypercholesterolemiaSupraventricular TachycardiaDermatologyCongenital IchthyosisMetabolicDuchenne Muscular Dystrophy(DMD)Familial Chylomicronemia Syndrome(FCS)ObesitySpinal Muscular Atrophy(SMA)NeurologyFibromyalgiaNarcolepsyNeurology OtherOncologyAcute Myeloid Leukemia(AML)Bl